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INTRODUCTION
Implant is one mean of contraception devices that is
placed under the skin. Implants contain steroid hor-
mones and can be used for 1 - 5 years; one of them
is levonorgestrel (LNG) implant.1,2
Norplant®, as first generation of LNG implant,
consisting 6 capsules, has been proven to be an ef-
fective long-term contraception for 25 years.3-6 On
later development7-10, the implant number has been
reduced to two rods and called Norplant2®, which
later renewed to Jadena® (in Indonesia) or Jadelle®
(in America).11,12
As the biggest acceptor of family planning country
in the world, Indonesia has developed its own implant
contraception which contains two LNG rods and
called Indoplant®.13,14 One LNG implant (Mono-
plant®) is hoped to be the best/most chosen for its
practicality (to insert and to remove), and also for its
effectiveness and safety for at least three years.
GENERAL DESCRIPTION FOR LEVO-
NORGESTREL IMPLANT
Drug Release System of Implants
In the last three decades, a lot of research have been
developed to determine the release control system of
drugs, usually to determine the effective concentration
of drugs pharmacologically. Drugs release control
system technology is really developing, especially for
oral and trans-dermal drugs or long-term drugs in-
jected to the body, there is an issue of body rejection
(bio-compatibility), and especially tissue rejection
(tissue compatibility). The bio-compatibility reaction
usually comes in toxic, carcinogenic, immunogenic,
and inflammatory reactions.15 This biocompatibility
is related to the implant material (bio-material) that’s
been used.16 Silicone, not only co-polymer dimethyl-
siloxane, but also methylvinylsiloxane, which has
been used since 1950, is the most compatible bioma-
terial.
Abstract
Objective: This research was conducted to measure levonorges-
trel serum concentration Monoplant® after six months of usage.
Method: Thirty healthy women, 20 - 40 years old, and after been
proven for fertility, had implants on their body. Levonorgestrel se-
rum levels were measured monthly from the first month to the sixth
month.
Result: Levonorgestrel serum concentration was still above 200
pg/ml until the sixth month. First month and second month serum
concentration was not recorded while data for the following months
were 338.9 pg/ml, 424.8 pg/ml, 320.3 pg/ml, and 337.5 pg/ml.
Conclusion: Levonorgestrel serum concentration in Monoplant®
users was still above contraceptive level until six months.
[Indones J Obstet Gynecol 2011; 35-3: 122-7]
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Abstrak
Tujuan: Penelitian ini dilakukan untuk mengetahui kadar levo-
norgestrel susuk satu batang Monoplant® sampai 6 bulan pema-
kaian.
Metode: Sebanyak 30 orang perempuan sehat, berusia 20 - 40
tahun, dan telah terbukti fertilitasnya, dilakukan pemasangan susuk.
Selanjutnya dilakukan pemeriksaan serum levonorgestrel setiap bu-
lan sampai bulan keenam.
Hasil: Kadar serum levonorgestrel hingga bulan keenam setelah
pemasangan susuk tetap di atas 200 pg/ml. Kadar pada bulan per-
tama dan bulan kedua tidak ada data, kadar pada bulan-bulan se-
lanjutnya adalah 338,9 pg/ml; 424,8 pg/ml; 320,3 pg/ml; dan 337,5
pg/ml.
Kesimpulan: Kadar levonorgestrel pemakai susuk Monoplant®
hingga bulan keenam masih di atas kadar kontrasepsi.
[Maj Obstet Ginekol Indones 2011; 35-3: 122-7]
Kata kunci: susuk satu batang Monoplant®, kadar levonorges-
trel
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Silastic cylinder (medical grade polydimethylsilox-
ane) has been used on humans as implants and for
other surgical means. This tube also has been placed
permanently inside the body since 1950. As example,
more than 200.00 hydrocephalus patients have used
this cylinder as cerebrospinal fluid drainage for the
rest of their lives without serious reaction to foreign
bodies. Also, medical glue (silicone type A) has been
long and massively used in surgery.
After implant is placed under the skin, there will
be tissue rejection reaction ,which is induced by tissue
damage that happens soon on insertion. Local inflam-
matory responses happen in sequelae of reactions:
neutrophil, polymorphonuclear, eosinophil, and ma-
crophage rejection. Later, tissue repair happens and
granulation tissue is formed. Macrophages do not
phagotize silastic cylinder, perivascular fibroblasts
will tend to isolate this cylinder around with shelter
or capsules of connective tissue. The formation of fi-
ber-capsule around the tube is not easy to be moved
and hard to pull when removing the implant.15
Since Folkman and Long (1964) found that silastic
cylinder can be used to distribute drugs because of
its sustain-release feature; also Dziuk and Cook, in
vitro, proved drugs that came out from silastic cylin-
der were always in constant concentration; then Segal
and Croxatto (1966) tried to use silastic cylinder that
was planted beneath the skin as a system to distribute
steroid hormones. This research became the founda-
tion and concept to develop long-term contraception
which we know as implant.17-19
First implant generation, Norplant®, consists of six
capsules containing LNG on silicone elastomer ma-
trix. After plantation, Norplant® soon releases 50 - 80
mcg LNG per day. On the first year of use, 40 - 50
mcg/day of LNG will be released. This number gradu-
ally decreases to 25 - 30 mcg/days on the fifth year
of usage. Despite this reduction, Norplant® has been
proved to successfully prevent pregnancy for seven
years, with pregnancy number cumulatively on se-
venth year is 1%.20,21
Later, second generation implant was developed,
Jadelle®, consisting only two rods. Because it uses
new elastomer technology with lower silicone con-
centration, the rod becomes more flexible and soft,
and drug release capability increases. Thus, 2 rods of
Jadelle® have the ability to release LNG as effective
as six capsules of Norplant®. Jadelle® on the first
month releases LNG in about 100 mcg/days then de-
creases to 40 mcg/day until the 12th month and con-
stantly releases 30 mcg/day on the 24th month. Ja-
delle® has been approved to be used for five years
with cumulative pregnancy number in the fifth years
is 1 %.22
Levonorgestrel Profile on Implant
Active hormone inside Norplant® and Jadena® is le-
vonorgestrel or LNG, with a chemical name of dex-
trorotatory isomer - 13ß-ethyl-17α-ethinyl-17ß-hydro-
xy,18,19-dinorpregn-4-en-20-yn-3-one, which is a
chemical derivative of 19-nortestosterone. LNG is a
steroid hormone, with a strong progesterone activity
and weak androgen activity, without estrogen. Chemical
structure from LNG can be viewed on Figure 1.23,24
Norgestrel consists of two stereoisomers: dextro-
norgestrel and levonorgestrel, only LNG is biologi-
cally active. LNG does not need bio-activation on the
liver to work because LNG itself is an active meta-
bolite. LNG bio-availability is almost 100%.24-26
Toxicology
Implant contraception system consists of two basic
components: progestin as bioactive, and polymer or
silastic or silicone elastomer as the mixing compo-
nents. Thus, researches on implant toxicology are also
designed to evaluate the progestin and polymer
used.27
Research of LNG toxicology is completely done.
Data about genotoxicity, carcinogenicity, effect on fe-
tus growth, and effect on reproduction, in animals and
humans, shows no toxicity as LNG given orally or in
injection.27
Also toxicology research for polymer or silicone elas-
tomer, which is used on Norplant® and Jadelle®, has
proven its safety to be used along with the implant. This
research is done on human and animal.27-29
Pharmacokinetic
Absorbtion
LNG serum concentration on average after Jadena®
is implanted is 437 pg/ml, while Norplant-2® stays at
425 pg/ml (Figure 2). Average concentration for both
implants are still above 300 pg/ml in a year. On the
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Figure 1. Levonorgestrel Chemical Structure (C21H28O2)
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second and third year, LNG concentration is higher
in women using Jadena® than in women using  Nor-
plant-2®. Although at the end of third year, LNG con-
centration in women using Jadena® becomes 275
pg/ml, this value is still 20% higher than Norplant-2®
and is still above limit value to prevent pregnancy
(200 mcg/ml).44 LNG concentration in serum is in-
fluenced by body weight, SHBG level, and its meta-
bolite clearance.17,24-26,30,31
Distribution and Excretion
After implanted, Norplant® releases 50 - 80 mcg of
LNG daily. Few months after Norplant® implantation,
LNG serum concentration is stable at 400 pg/ml. Af-
ter five years of usage, it becomes 200 pg/ml. LNG
release level of Jadena® is about 100 mcg/day on first
month. Later, it declines to 40 mcg/day until 12
months and stays in 30 mcg/days at the 24th month.
Serum concentration of 772 pg/ml is achieved in two
days after implantation. Serum level after one, six,
and three years are 437, 371, and 270 pg/ml, respec-
tively.33
LNG mostly (> 90%) stays in blood and is bound
to Sex Hormone Binding Globulin (SHBG) and albu-
min, only free LNG is biologically active.26,31 There
is a strong correlation between LNG concentration
and SHBG. Level of SHBG will decrease following
elevation of LNG concentration. Afterwards, SHBG
will still be low following the reduction of LNG le-
vel.17
Most of LNG (40 - 68%) is excreted through urine,
and 16 - 48% through feces. Soon after removing
Norplant® outside the body, concentration of LNG
will be decreased to less than 100 pg/ml and in 5 -
14 days, the concentration cannot be measured any-
more.17,32,34
RESEARCH AND DEVELOPMENT
MONOPLANT® IMPLANT
Monoplant® only contains progestin hormone, levo-
norgestrel. This implant consists of one flexible rod
and inside, it contains same mixture amount as LNG
with elastomer silicone. Implant rod is covered with
thin-walled silicone (same with the one used on Ja-
delle® or Jadena®), and each pole is covered with Si-
lastic (polydimethyl-siloxane) Medical Grade Adhe-
sive. Every implant stick is 43 - 44 mm length and
2,5 - 2,6 mm in diameter, and containing 160 mg
LNG as shown in Figure 3.33,35
Substance used to make Monoplant® is not a new
drug. LNG has been used for more than 30 years for
contraception pills (combination pill and minipill) and
implant.35
Monoplant® is predicted to be effective as contra-
ception for three years. Because this ALKON is pro-
duced in Indonesia, advantages that will be gained are
single implantation for three years, no need for rou-
tine control, cheaper so relatively affordable, and ava-
ilable in most health services. Monoplant® is a single
rod, its insertion and removal are easier compared
than any other implant.
METHOD
This research is a second phase Clinical Trial with
pre and post design. It was held in Jakarta for six
months with women subjects aged 20 - 40 years who
still want to have next pregnancy.
Considering that this research was clinical trial
phase two (done for the first time on patient), which
was directed to evaluate whether drugs give therapeu-
tic effect, sample size in this research was limited to
10 - 20 subjects36 or 20 - 100 subjects.37 Using nu-
meric sample formula extraction for two paired
groups, sample requirement was 22 subjects. In this
research, it was agreed to use 30 subjects (recommen-
dation from Research Ethics FMUI was 10 patients).
If the subjects had met all the requirement (inclu-
sion and exclusion) and had been willing to sign in-
formed consent, then the subject would have been
categorized to research subject candidate. Later, re-
search questionaire should be filled, and in four weeks
before insertion, physical examination and laborato-
rium screening would be done.
After research subjects meet criteria mentioned
above, Monoplant® could be inserted on menstruation
period (day 1 to day 7). Subjects then would be fol-
lowed for six months, revisitation would be done in
the 4th week each month. On those periods, beside
physical examination and side-effect evaluation,
LNG, estrogen (E), and progesteron (P) examination
were also done. Another biochemical examinations
were triglyceride, total cholesterol, High Density
Lipoprotein (HDL) and Low Density Lipoprotein
(LDL), and also random blood glucose. Endometrium
thickness and cervix discharge were also measured.
RESULTS and DISCUSSION
Research was conducted in Klinik Raden Saleh,
Jakarta, and held between 2009 and 2010, as long as
6 months. Research subjects were women 20 - 40
years old who fulfilled inclusion criteria, and still
wanted pregnancy after implant was removed from
them.
As many as 30 family planning acceptors had ap-
proved to be chosen as subjects and follow this Mo-
noplant® implant research. All subjects finished this
research on schedule, six months. No subjects re-
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Figure 3. Norplant® capsules and Jadena® rod (and Monoplant®)
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quested to have their implants removed before re-
search is over. Even, if allowed, they were all willing
to use it untill the third year.
Subject Characteristics
General subject characteristics (distribution and fre-
quency) can be seen on Table 1. General charac-
teristics are age, education level, partner’s education
level, and history of contraception usage before.
Table 1. Characteristics of subjects by age, education, parity,
and history of contraceptive use (n = 30)
Variable
Age (years)*
• Mean** 31.6 ± 5.5
• Median† 32.5 (20 - 40)
Education (n.%)
• Elementary school  6 (20.0)
• Junior high school  6 (20.0)
• Senior high school 16 (53.3)
• Bachelor degree  2 (6.7) 
Parity (n)†  2 (1 - 5)
History of contraception (n.%)
• Injections 18 (60.0)
• Pills  5 (16.7)
• implants  3 (10.0)
• IUD  1 (3.3) 
• Others  1 (3.3) 
• Never  2 (6.7) 
* Normality test of Kolmogorov-Smirnov and Shapiro-Wilk (p = 0.164)
** Mean ± SD
† Median (Minimum-Maximum)
It can be seen that on average subjects’ age was
31 years old (31.6 ± 5.5 year), with the youngest age
of 20 years old and the oldest of 40 years old. Sta-
tistically, distribution of subjects’ age using Kolmo-
gorov-Smirnov and Shapiro-Wilk test was normal (p
> 0.05), with a p value of 0.146.
All subjects had formal education, mostly senior
high school level (53.3%). Most were well educated
enough (above Junior Highschool) because only 20%
subjects finished their education to elementary school.
All subjects to still in marriage and generally had
two children, with the smallest parity of one, and the
biggest of five. All subjects still wanted to have an-
other child or wasn’t sure to terminate their fertility.
Because of those reasons, they were willing to use
Monoplant® for three years.
Most of the subjects (93.3%) had used contracep-
tion before this research, and stopped for six years or
more. The chosen contraception was hormonal
(86.7%), 10% of them had used six capsules of im-
plant, Norplant®.
Levonorgestrel Concentration
LNG examination (Table 2.) was done in two differ-
ent laboratories: Makmal Terpadu FMUI-Cipto Ma-
ngunkusumo Hospital, Jakarta, Indonesia and Popu-
lation Council New York, USA. All subjects’ serum
for LNG examination from the 1st month to the 6th
month was examined in Makmal. Only a part of sub-
ject’s serum (from the 3rd to the 6th month) was exa-
mined in USA because left serum amount was not
sufficient to be transferred (at least 1 ml). The result,
most of the LNG level serums examined in Makmal
were low, but the concentration became higher if they
were re-examined in USA. Statistically, distribution
of LNG concentration (in Makmal and USA), using
normality test of Kolmogorov-Smirnov and Shapiro-
Wilk, howed normal data distribution (p > 0.05), with
p = 0.085 for Makmal LNG concentration and p =
0.072 for USA LNG concentration.
On average, LNG serum concentration in Makmal
laboratory after Monoplant® implant inserted was
237.5 pg/ml on the first month, above the concentra-
tion threshold of LNG (200 pg/ml; this concentration
has contraceptive effect).20 Then, on the 2nd month,
the concentration doubled to 536.7 pg/ml, but with a
wide range, 61.9 pg/ml to 1352 pg/ml, declining fast
on the 3rd month to 176.6 pg/ml, dan then reducing
slowly in the 6th month to 126.8 pg/ml. Because of
that, after the 3rd month, LNG serum concentrations
on average were under 200 pg/ml; moreover, it
reached 19 pg/ml on the 6th month in one research
subject. Vice versa, result of serum LNG concentra-
tion which was examined on USA laboratory stayed
in high value, far above effective concentration.
Using Friedman test, changes in LNG concentra-
tion every month was statistically significant (p <
0.01). However, on post hoc analysis using Wilcoxon
Signed Ranks, it showed that difference LNG concen-
tration between the 1st and the 4th month (p = 0.271),
Table 2. Levonorgestrel concentration after Monoplant® implantation
LNG (pg/ml)
Lab. Makmal Lab. USA
N Mean Min Max N Mean Min Max
Month 1 30 237.5 36.6  520.1
Month 2 30 536.7 61.9 1352.1
Month 3 30 176.6 59.0  409.0 11 338.9 231.2 501.5
Month 4 30 195.1 46.6  510.5  8 424.8 287.5 608.3
Month 5 30 163.2 25.0  315.9 15 320.3 115.5 484.3
Month 6 29 126.8 19.0  277.0 13 337.5 187.5 532.8
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and between the 3rd month and the 5th month (p =
0.185 to have a p value of > 0.05 which meant that
there was no significant LNG serum concentration
differences on those months.
Generally, although it has been seen that USA se-
rum LNG concentrations were two times that of Mak-
mal, linear regression analysis showed Adjusted R
Square = 0.045, which meant that both USA and Mak-
mal LNG serum concentration had a weak correlation
power. So, LNG serum concentration measured in
Makmal couldn’t predict LNG serum concentration
measurement in USA, and vice versa. If it was
needed, LNG concentration analysis would be done
for each group, Makmal result and USA result.
Sivin (1997) 32 in a multi center research (North
and South America, Europe, and Asia) about Jadelle®
revealed that progestin implant contraception effect
depended on the diffusion ability of LNG from its
reservoir to circulation system. Furthermore, LNG
was circulating and bound to SHBG, and only free
LNG gave effect to target organ.
A few moments after implant insertion, LNG could
be detected in serum. Maximum concentration was
achieved in 24 - 72 hours after insertion and would
decline on the first week,34 reaching median concen-
tration on the first month,32 and continuously decreas-
ing in three years of usage.33 LNG average serum
concentration on the first month after Jadelle® inser-
tion was 435 pg/ml and would decrease to 280 pg/ml
by the end of third year. Although Jadelle® was only
recommended for three years of contraception, this
research was continued to 7 years. LNG serum con-
centration in the end of seventh year was 224 pg/ml.
Different from Sivin’s research, Monoplant® does
not show distribution of LNG concentration as dis-
covered before, especially the 1st month concentra-
tion. Jadelle® LNG concentration which was usually
very high on insertion (about 1000 pg/ml) and reached
median concentration (about 500 pg/ml) in the end of
the first month, did not show in Monoplant®. Mo-
noplant® serum concentration in the end of the first
month was only 237.5 pg/ml, and median concentra-
tion was reached on the second month (536.7 pg/ml),
then LNG serum concentration would decrease gradu-
ally.
Not only LNG concentration distribution pattern
looked different from Jadelle®, it’s hard to explain
the low LNG concentration on the first month (only
one fourth of Jadelle® concentration) and how its con-
centration rose again on second month. Another thing
was the range of result, which was very wide, espe-
cially in the second month, the lowest concentration
was 61.9 pg/ml and the highest 1352 pg/ml (see Table
2). Although data distribution of Makmal LNG serum
concentration was statistically normal, however, ac-
curacy of examination result seemed to be low, so the
data validity was also low.
Reviews about Makmal LNG low concentration
had been done, presumably related to the lack of a
functioning ß Counter machine. Although results of
the QC (Quality Control) showed normal result, the
enumerator couldn’t read titanium isotope which had
been used in this LNG examination series. Actually
whole series of LNG concentration examination had
been done properly according to the guidelines pro-
vided. LNG examination was done simultaneously for
all serum collected from the 1st month to the 6th
month. All serums were still in good condition, not
one had lysis. Most of the examination process was
done in Makmal, serum collection, storage, and count-
ing, except for LNG extraction that was carried out
outside out Makmal because the existing equipment
was damaged. Because the low results of Makmal ex-
amination happened in nearly all subjects which pre-
sumably related to examination procedure, so statis-
tically, the data obtained had a systematic error (sys-
tematic error, not random error). This systematic error
was caused by weak internal validity (measuring in-
strument). The reliability test for Makmal data distri-
bution was also low with Cronbach’s alpha value =
0.371, data otherwise reliable if Cronbach alpha value
is over 0.7.
Realizing there were mistakes in reading LNG con-
centration because of malfunctioning ß enumerators,
the next LNG serum concentration examination were
only carried out in Population Council Laboratories,
New York, USA. Also, LNG data that will be dis-
cussed next are the data of LNG examination from
USA lab.
Different from Makmal result (Table 2), LNG se-
rum examination in Population Council Laboratories,
New York, USA showed higher concentration, even
in the sixth month, the average concentration was far
above 200 pg/ml, exactly 337.5 pg/ml. average LNG
concentration every month was relatively stable.
There was no data about concentration on the first
and second month, but LNG concentration in the fol-
lowing months were 338.9 pg/ml, 424.8 pg/ml, 320.3
pg/ml, and 337.5 pg/ml. Although there was a little
fluctuation, changes statistically (Friedman test)
showed no differences in levels of significance (p =
0.508).
Because LNG concentration at the end of the sixth
month was above effective contraceptive level (200
pg/ml), reaching 337.5 pg/ml; even which was not
much different from Jadelle® acceptor level of serum
LNG in the same month, 357 pg/ml, then subjects
could still use Monoplant® as contraception until the
36th month, as recomended. Another findings such as
hormonal, blood chemistry, and other clinical findings
will be delivered at the next discussion.
CONCLUSIONS
Levonorgestrel serum concentration in Monoplant®
user until the sixth month is still far above contracep-
tive level.
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